Approval · Notice of Compliance 30731 · 2023
OXLUMO: Notice of Compliance 30731
Issued May 12, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 30731
- Date
- May 12, 2023
- Company
- Alnylam Netherlands B.V.Amsterdam, Netherlands
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the Product Monograph. Revision to the indication.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| OXLUMO | Not yet assigned | — |
Medicinal ingredients
- LUMASIRAN SODIUM 94.5 MG per 0.5ML